SWX:BSLNBiotechs
Basilea Pharmaceutica (SWX:BSLN) Margin Slide Challenges Bullish Growth Narratives After FY 2025 First Half
Basilea Pharmaceutica (SWX:BSLN) has just posted its FY 2025 numbers with first half revenue of CHF103.96 million and basic EPS of CHF1.29, following FY 2024 second half revenue of CHF132.25 million and basic EPS of CHF4.70. The company has seen revenue move from CHF76.29 million in FY 2024 first half to CHF132.25 million in second half and then CHF103.96 million in FY 2025 first half, while basic EPS shifted from CHF1.72 to CHF4.70 and then CHF1.29. This sets up a results picture that puts...